Why the FDA hearing on Vanda Pharmaceuticals’ HETLIOZ could reshape drug approval challenges
FDA grants rare hearing to review Vanda Pharmaceuticals’ HETLIOZ jet lag application. Discover what this regulatory fight could mean for circadian medicine.
Pharma & Biotech